Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Vir biotechnology, inc. symbols : SNY save search
The Global Antiviral Drugs Market to Exhibit Growth at a Paltry CAGR of ~4% by 2027 | DelveInsight
Published: 2023-02-02 (Crawled : 16:00) - prnewswire.com
NVSEF | News | $96.0 0.94% 6.88% 0
|
Health Technology
|
| O: -1.71%
H: 0.0%
C: 0.0%
VTRS | News A | $11.55 1.67% 1.65% 4.4M
|
Health Technology
|
| O: -0.16%
H: 0.08%
C: -0.41%
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: -1.87%
H: 0.01%
C: -0.55%
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: -1.16%
H: 1.98%
C: 1.56%
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: -1.28%
H: 3.64%
C: 3.48%
ABBV | News | $167.8 -1.03% -0.02% 2.9M
|
Health Technology
|
| O: -0.46%
H: 0.0%
C: -0.75%
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: 0.62%
H: 2.22%
C: 1.94%
TNXP | $0.16 2.04% 1.2% 940K
|
Health Technology
|
| O: 0.85%
H: 5.08%
C: 0.0%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -1.44%
H: 0.0%
C: 0.0%
GILD | $67.08 0.08% 0.06% 6.2M
|
Health Technology
|
| O: -1.95%
H: 0.16%
C: -1.18%
global antiviral growth market
Seasonal Influenza Market to Proliferate at a CAGR of 6.1% During the Forecast Period (2022-2032), Assesses DelveInsight
Published: 2022-11-23 (Crawled : 16:00) - prnewswire.com
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: -0.66%
H: 1.21%
C: 0.07%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: 0.23%
H: 0.0%
C: 0.0%
COCP | $1.5559 -0.39% -1.39% 3.9K
|
Health Technology
|
| O: 2.29%
H: 3.39%
C: 1.12%
influenza market
Alnylam Announces Appointment of Elliott Sigal, M.D., Ph.D., to Board of Directors
Published: 2022-08-24 (Crawled : 21:00) - biospace.com/
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
|
| O: -4.66%
H: 0.0%
C: -1.69%
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: -1.0%
H: 3.6%
C: 1.66%
SURF | $1.07 -0.93% -1.41% 0
|
Health Technology
|
| O: 1.26%
H: 3.73%
C: 0.62%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -1.48%
H: 0.0%
C: 0.0%
ALNY | $143.8 -1.55% -1.58% 400K
|
Health Technology
|
| O: 0.44%
H: 2.9%
C: 1.45%
ADAP | $1.08 -5.26% -5.07% 790K
|
Health Technology
|
| O: 0.46%
H: 5.04%
C: 1.83%
US Food and Drug Administration Revises Emergency Use Authorization for Sotrovimab Due to Omicron BA.2 Subvariant
Published: 2022-03-25 (Crawled : 21:00) - biospace.com/
GLAXF | News | $19.54 -3.77% -14.18% 170
|
Health Technology
|
| O: 4.57%
H: 0.0%
C: -3.26%
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
XNCR | $19.02 3.54% 3.57% 760K
|
Health Technology
|
| O: -0.7%
H: 1.94%
C: -1.47%
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: -1.07%
H: 0.8%
C: -12.62%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: 0.0%
drug food authorization emergency use authorization
GSK and Vir Submit Emergency Use Authorization Application to FDA for Intramuscular Administration of Sotrovimab for the Early Treatment of COVID-19
Published: 2022-01-13 (Crawled : 15:30) - biospace.com/
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: 0.29%
H: 0.0%
C: 0.0%
XNCR | $19.02 3.54% 3.57% 760K
|
Health Technology
|
| O: 0.38%
H: 1.12%
C: -1.31%
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: 1.05%
H: 1.98%
C: -6.88%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -0.74%
H: 0.0%
C: 0.0%
covid-19 treatment fda application covid authorization merge emergency use authorization
Xevudy (Sotrovimab) Granted Marketing Authorization by the European Commission for the Early Treatment of COVID-19
Published: 2021-12-17 (Crawled : 13:30) - globenewswire.com
GLAXF | News | $19.54 -3.77% -14.18% 170
|
Health Technology
|
| O: 2.36%
H: 0.46%
C: 0.46%
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
|
| O: -0.48%
H: 0.0%
C: 0.0%
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: 0.86%
H: 0.0%
C: 0.0%
XNCR | $19.02 3.54% 3.57% 760K
|
Health Technology
|
| O: -0.45%
H: 0.0%
C: 0.0%
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: -4.59%
H: 0.0%
C: 0.0%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: 0.22%
H: 0.0%
C: 0.0%
covid-19 treatment europe granted covid authorization grant
Preclinical Studies Demonstrate Sotrovimab Retains Activity Against the Full Combination of Mutations in the Spike Protein of the Omicron SARS-CoV-2 Variant
Published: 2021-12-07 (Crawled : 09:00) - globenewswire.com
GLAXF | News | $19.54 -3.77% -14.18% 170
|
Health Technology
|
| O: 5.22%
H: 0.0%
C: -1.25%
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
|
| O: 3.63%
H: 0.0%
C: 0.0%
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: 0.14%
H: 0.0%
C: 0.0%
XNCR | $19.02 3.54% 3.57% 760K
|
Health Technology
|
| O: -2.12%
H: 4.74%
C: 2.8%
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: -6.42%
H: 8.6%
C: 8.45%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
preclinical sars-cov-2 pre-clinical
Preclinical Data Demonstrate Sotrovimab Retains Activity Against Key Omicron Mutations, New SARS-CoV-2 Variant
Published: 2021-12-02 (Crawled : 08:00) - globenewswire.com
GLAXF | News | $19.54 -3.77% -14.18% 170
|
Health Technology
|
| O: -0.05%
H: 0.0%
C: -1.97%
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: 0.0%
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: 0.58%
H: 0.5%
C: -0.36%
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: 20.02%
H: 0.19%
C: -12.53%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -0.19%
H: 0.0%
C: 0.0%
preclinical sars-cov-2 pre-clinical
GSK and Vir Biotechnology Announce United States Government Agreements to Purchase Sotrovimab, a COVID-19 Treatment
Published: 2021-11-17 (Crawled : 12:00) - globenewswire.com
GLAXF | News | $19.54 -3.77% -14.18% 170
|
Health Technology
|
| O: 1.43%
H: 2.31%
C: 2.27%
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: -0.28%
H: 0.0%
C: 0.0%
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: 9.97%
H: 4.0%
C: -6.28%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
covid treatment biotech technology iot covid-19
Primary endpoint met in COMET-TAIL Phase 3 trial evaluating intramuscular administration of sotrovimab for early treatment of COVID-19
Published: 2021-11-12 (Crawled : 13:00) - biospace.com/
GLAXF | News | $19.54 -3.77% -14.18% 170
|
Health Technology
|
| O: 1.8%
H: 0.0%
C: -0.31%
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: 0.93%
H: 0.0%
C: 0.0%
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: 4.66%
H: 0.0%
C: 0.0%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -0.66%
H: 0.0%
C: 0.0%
covid treatment phase 3 trial
Vaxcyte Appoints Carlos Paya and Michael Kamarck to Its Board of Directors
Published: 2021-10-28 (Crawled : 13:00) - globenewswire.com
PPRUF | News | $345.01 1.47% 37.56% 1.6K
|
Consumer Non-Durables
|
| O: 1.59%
H: 2.24%
C: -0.46%
PPRUY | News | $34.9595 3.46% -0.11% 390K
|
Manufacturing
|
| O: 0.51%
H: 0.92%
C: 0.92%
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: -0.26%
H: 2.92%
C: -1.13%
PCVX | $60.3 -0.95% -1.05% 700K
|
Health Technology
|
| O: 0.27%
H: 6.61%
C: 5.43%
STRO | $3.47 -6.72% -7.2% 730K
|
Health Technology
|
| O: 0.1%
H: 5.38%
C: 5.02%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: 0.83%
H: 1.2%
C: 0.32%
GSK and Vir Biotechnology Announce Joint Procurement Agreement with European Commission for COVID-19 Treatment, Sotrovimab
Published: 2021-07-28 (Crawled : 12:00) - biospace.com/
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: -1.06%
H: 1.31%
C: 1.02%
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: 1.54%
H: 4.68%
C: 0.14%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -0.5%
H: 1.7%
C: 1.4%
covid treatment europe biotech technology iot covid-19
Global $9.5 Billion Influenza Vaccines Market to 2027
Published: 2021-07-27 (Crawled : 11:00) - prnewswire.com
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: 0.41%
H: 1.0%
C: 0.87%
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: -0.68%
H: 2.23%
C: -0.76%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -0.54%
H: 0.65%
C: 0.49%
vaccine influenza
GSK and Vir Biotechnology Announce Continuing Progress of the COMET Clinical Development Program for Sotrovimab
Published: 2021-06-21 (Crawled : 12:00) - biospace.com/
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: -0.15%
H: 0.33%
C: 0.0%
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: 0.5%
H: 6.27%
C: 5.89%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -0.32%
H: 0.17%
C: -0.13%
ev biotech technology iot
GSK and Vir Biotechnology Announce Sotrovimab (VIR-7831) Receives Emergency Use Authorization from the US FDA for Treatment of Mild-to-Moderate COVID-19 in High-Risk Adults and Pediatric Patients
Published: 2021-05-26 (Crawled : 23:00) - globenewswire.com
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: -0.8%
H: 0.69%
C: 0.23%
LLY | News | $732.2 -1.81% -0.84% 1.7M
|
Health Technology
|
| O: -0.17%
H: 0.36%
C: -0.72%
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: 4.2%
H: 0.3%
C: -9.4%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -0.5%
H: 0.32%
C: -1.27%
covid treatment fda risk biotech technology iot merge authorized emergency use authorization
CORRECTION -- EMA Issues Positive Scientific Opinion on GSK and Vir Biotechnology’s Sotrovimab For the Early Treatment of COVID-19
Published: 2021-05-21 (Crawled : 14:00) - globenewswire.com
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: -0.26%
H: 0.26%
C: -0.21%
LLY | News | $732.2 -1.81% -0.84% 1.7M
|
Health Technology
|
| O: 0.24%
H: 0.96%
C: -0.06%
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: 1.75%
H: 0.13%
C: -1.44%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -0.43%
H: 0.2%
C: 0.02%
covid treatment positive biotech technology iot ema
EMA Issues Positive Scientific Opinion on GSK and Vir Biotechnology’s Sotrovimab For the Early Treatment of COVID-19
Published: 2021-05-21 (Crawled : 12:15) - globenewswire.com
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: -0.26%
H: 0.26%
C: -0.21%
LLY | News | $732.2 -1.81% -0.84% 1.7M
|
Health Technology
|
| O: 0.24%
H: 0.96%
C: -0.06%
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: 1.75%
H: 0.13%
C: -1.44%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -0.43%
H: 0.2%
C: 0.02%
covid treatment positive biotech technology iot ema
GSK and Vir Biotechnology Announce the Start of the EMA Rolling Review of VIR-7831 (sotrovimab) for the Early Treatment of COVID-19
Published: 2021-05-07 (Crawled : 14:00) - biospace.com/
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: 0.5%
H: 0.84%
C: 0.66%
LLY | News | $732.2 -1.81% -0.84% 1.7M
|
Health Technology
|
| O: 0.48%
H: 0.74%
C: 0.31%
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: 3.24%
H: 2.94%
C: 0.02%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: 0.92%
H: 0.88%
C: 0.66%
covid treatment biotech technology iot ema
GSK and Vir Biotechnology Announce EMA Review of Dual-Action Monoclonal Antibody VIR-7831 for the Early Treatment of COVID-19
Published: 2021-04-15 (Crawled : 14:00) - globenewswire.com
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: 4.23%
H: 1.59%
C: 0.08%
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: 0.37%
H: 2.8%
C: -1.49%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: 0.76%
H: 0.61%
C: 0.14%
covid treatment antibody biotech technology iot ema
Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19
Published: 2021-03-29 (Crawled : 14:00) - biospace.com/
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: -0.82%
H: 1.18%
C: 0.88%
LLY | News | $732.2 -1.81% -0.84% 1.7M
|
Health Technology
|
| O: -0.35%
H: 1.63%
C: 0.91%
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: -1.46%
H: 1.02%
C: -4.73%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -0.56%
H: 0.83%
C: 0.57%
covid phase 2 risk positive topline biotech technology iot trial
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
BOF | $2.08 77.78% 39.06% 110M
|
BHIL | $0.1793 -4.37% 19.24% 340K
|
Agriculture, Forestry, Fishing ...
UMAC | $1.48 -1.33% 14.87% 20K
|
CI | $352.28 -0.11% 13.53% 2
|
Health Services
CIG.C | $2.89 -1.37% 12.8% 2.3K
|
n/a
MTH | $154.69 -2.21% 12.68% 450K
|
Consumer Durables
HCP | News | $31.41 7.75% 11.26% 17M
|
TSLA | News | $162.13 12.06% 10.13% 170M
|
Consumer Durables
BMTX 4 | $1.545 0.98% 10.03% 2.5K
|
Information
TAL | $12.26 0.57% 9.22% 12M
|
Consumer Services
Your saved searches
Save your searches and get alerts when important news are released.